A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis.

BACKGROUND It is uncertain whether patients with proximal deep-vein thrombosis should be treated with streptokinase followed by intravenous heparin or with intravenous heparin alone. Published reports indicate that streptokinase plus heparin increases the risk of bleeding, including central nervous system bleeding and death, but decreases the risk of postphlebitic syndrome. Previous recommendations regarding these treatments have not considered patients' preferences or the values they attach to the possible outcomes of therapy. METHODS We used decision analysis to combine published estimates of the probabilities of various adverse outcomes of treatment (bleeding, pulmonary embolism, postphlebitic syndrome, and death) with the values patients placed on these outcomes. We questioned 36 patients about the values they attached to each outcome. Sixteen patients had had deep-vein thrombosis, and 20 had not. RESULTS By the values they attached to the outcomes, all 36 patients indicated that they were unwilling to accept an increased risk of death to avoid postphlebitic syndrome. According to the decision analysis, heparin alone was the better treatment for all 36 patients. As compared with streptokinase plus heparin, heparin alone provided 29 days of additional life expectancy over the predicted life expectancy of 20 years. Although the difference between the two treatments was small, heparin alone remained the better treatment in sensitivity analyses that examined the reasonable ranges of probabilities of the clinical outcomes. CONCLUSIONS The values patients placed on the outcomes of treatment for deep-vein thrombosis support the use of heparin alone over the combined use of streptokinase and heparin.

[1]  N. Browse,et al.  Streptokinase and Deep Vein Thrombosis , 1968, British medical journal.

[2]  V. Kakkar,et al.  Treatment of Deep Vein Thrombosis. A Trial of Heparin, Streptokinase, and Arvin , 1969, British medical journal.

[3]  M. Tsapogas,et al.  Controlled study of thrombolytic therapy in deep vein thrombosis. , 1973, Surgery.

[4]  L. Kurland,et al.  Natural History of Stroke in Rochester, Minnesota, 1955 Through 1969: An Extension of a Previous Study, 1945 Through 1954 , 1973, Stroke.

[5]  C. Chesterman,et al.  Controlled Trial of Ancrod and Streptokinase in the Treatment of Deep Vein Thrombosis of Lower Limb , 1974, British journal of haematology.

[6]  J. Rösch,et al.  Comparison of heparin and streptokinase in the treatment of venous thrombosis. , 1975, The American surgeon.

[7]  L. Widmer,et al.  Treatment of deep vein thrombosis with streptokinase. , 1975, British medical journal.

[8]  E W Salzman,et al.  Management of heparin therapy: Controlled prospective trial. , 1975, The New England journal of medicine.

[9]  J. Rösch,et al.  Deep Vein Thrombosis Treated With Streptokinase or Heparin , 1976, Angiology.

[10]  R. Bieger,et al.  Is streptokinase useful in the treatment of deep vein thrombosis? , 2009, Acta medica Scandinavica.

[11]  S. Zetterquist,et al.  Streptokinase treatment of deep venous thrombosis of the lower extremity. Clinical, phlebographic and plethysmographic evaluation of early and late results. , 2009, Acta medica Scandinavica.

[12]  M. Mant,et al.  HÆMORRHAGIC COMPLICATIONS OF HEPARIN THERAPY , 1977, The Lancet.

[13]  H. Arnesen,et al.  A prospective study of streptokinase and heparin in the treatment of deep vein thrombosis. , 2009, Acta medica Scandinavica.

[14]  G. Torrance,et al.  The utility of different health states as perceived by the general public. , 1978, Journal of chronic diseases.

[15]  S. Benatar,et al.  A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: An interim report of a prospective trial , 1979, The British journal of surgery.

[16]  G. Savidge,et al.  Rapid thrombolysis and preservation of valvular venous function in high deep vein thrombosis. A comparative study between streptokinase and heparin therapy. , 2009, Acta medica Scandinavica.

[17]  J. Wilson,et al.  Heparin therapy: a randomized prospective study. , 1979, American heart journal.

[18]  G. Nylander,et al.  Comparison of streptokinase with heparin: late results in the treatment of deep venous thrombosis. , 2009, Acta medica Scandinavica.

[19]  V. Marder,et al.  Thrombolytic therapy in thrombosis: a National Institutes of Health consensus development conference. , 1980, Annals of internal medicine.

[20]  B. Fagher,et al.  Heparin treatment of deep vein thrombosis. Effects and complications after continuous or intermittent heparin administration. , 2009, Acta medica Scandinavica.

[21]  J R Beck,et al.  A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. , 1982, The American journal of medicine.

[22]  A. Høiseth,et al.  Streptokinase of heparin in the treatment of deep vein thrombosis. Follow-up results of a prospective study. , 2009, Acta medica Scandinavica.

[23]  A. Hartmann,et al.  Heparin treatment of deep venous thrombosis in 280 patients: symptoms related to dosage. , 2009, Acta medica Scandinavica.

[24]  J. Buring,et al.  Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. , 1984, The American journal of medicine.

[25]  D. Lawrence,et al.  Hemodynamic and clinical assessment after therapy for acute deep vein thrombosis. A prospective study. , 1985, American journal of surgery.

[26]  E. Eldrup,et al.  Streptokinase therapy in the routine management of deep venous thrombosis in the lower extremities. A retrospective study of phlebographic results and therapeutic complications. , 2009, Acta medica Scandinavica.

[27]  Can thrombolytics prevent post-phlebitic syndrome and thrombo-embolic disease? , 1986, Haemostasis.

[28]  E F Cook,et al.  Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. , 1987, The American journal of medicine.

[29]  A. Misiak,et al.  Hazards of thrombolytic therapy in deep vein thrombosis , 1987, The British journal of surgery.

[30]  Sol Sherry,et al.  Thrombolytic Therapy: Current Status , 1988 .

[31]  H. Riess,et al.  Thrombectomy, lysis, or heparin treatment: concurrent therapies of deep vein thrombosis: therapy and experimental studies. , 1989, Seminars in thrombosis and hemostasis.

[32]  R. Mcnutt.  Measuring patient preferences for health outcomes: a decision analytic approach. , 1989, Patient education and counseling.

[33]  L. Rogers,et al.  Streptokinase therapy for deep vein thrombosis: a comprehensive review of the English literature. , 1990, The American journal of medicine.

[34]  N. Boyd,et al.  Whose Utilities for Decision Analysis? , 1990, Medical decision making : an international journal of the Society for Medical Decision Making.

[35]  R. Califf,et al.  Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long-term prognosis. , 1990, Journal of the American College of Cardiology.

[36]  J. Gore,et al.  Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. , 1991, Circulation.

[37]  S. Sherry.  Thrombolytic therapy for noncoronary diseases. , 1991, Annals of emergency medicine.

[38]  S. Goldhaber.  Recent advances in the diagnosis and lytic therapy of pulmonary embolism. , 1991, Chest.

[39]  F. Van de Werf,et al.  The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group. , 1992, The New England journal of medicine.

[40]  E. Braunwald,et al.  Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion , 1993, The Lancet.